{"id":667,"date":"2023-04-17T12:30:05","date_gmt":"2023-04-17T11:30:05","guid":{"rendered":"https:\/\/project.eortc.org\/e2-radiate\/?p=667"},"modified":"2024-02-07T13:26:38","modified_gmt":"2024-02-07T12:26:38","slug":"oligocare-2000-patients-enrolled","status":"publish","type":"post","link":"https:\/\/project.eortc.org\/e2-radiate\/2023\/04\/17\/oligocare-2000-patients-enrolled\/","title":{"rendered":"OligoCare: 2000 patients enrolled"},"content":{"rendered":"

OligoCare: 2000 patients enrolled<\/h1><\/div><\/div><\/div><\/div><\/div>

We are delighted to announce that on the 11th of April 2023, the RP-1822 OligoCare<\/a> cohort of the 1811-E\u00b2-RADIatE platform successfully enrolled its 2000th patient<\/span>, marking a significant milestone for the cohort initiated in 2019.<\/span><\/p>\n

The 2000th patient was enrolled by the Istituto Europeo di Oncologia<\/span>.<\/span><\/p>\n

The OligoCare cohort has been performing exceptionally well, with a total of 701 patients enrolled in 2022 alone. The average accrual rate of patients has been an impressive 58 per month.<\/span><\/p>\n<\/div>

<\/div><\/div><\/div>
\"OligoCare<\/span><\/div>
<\/div><\/div><\/div>

Professor Filippo Alongi will present new results from the first patients included in the ESTRO\/EORTC E\u00b2-RADIatE OligoCare cohort at ESTRO 2023 in Vienna. To learn more, please read this article<\/a>.<\/span><\/p>\n

We would like to thank once again all of the investigators who have contributed to the success of this cohort. We would like to give special recognition to the top three recruiting investigators, namely, Prof. Marta Scorsetti<\/strong>, Prof. Filippo Alongi<\/strong>, and Prof. Umberto Ricardi<\/strong>. We are also extremely grateful for the efforts and continued support of our investigators, staff, and most importantly the 2000 patients involved. You all played a crucial role in achieving these impressive numbers.<\/span><\/p>\n

The E\u00b2-RADIatE platform is supported by Walgreens Boots Alliance<\/a>.<\/span><\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":731,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-667","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts\/667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/comments?post=667"}],"version-history":[{"count":6,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts\/667\/revisions"}],"predecessor-version":[{"id":732,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts\/667\/revisions\/732"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/media\/731"}],"wp:attachment":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/media?parent=667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/categories?post=667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/tags?post=667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}